Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  20.00 1.81% 1,125.00 32,854 16:35:19
Bid Price Offer Price High Price Low Price Open Price
1,060.00 1,125.00 1,092.50 1,080.00 1,092.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -10.61 -16.00 811
Last Trade Time Trade Type Trade Size Trade Price Currency
16:41:31 O 3,000 1,105.00 GBX

Renalytix Ai (RENX) Latest News (1)

More Renalytix Ai News
Renalytix Ai Investors    Renalytix Ai Takeover Rumours

Renalytix Ai (RENX) Discussions and Chat

Renalytix Ai (RENX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-24 16:16:451,105.003,00033,150.00O
2021-06-24 16:07:401,095.002,50027,375.00O
2021-06-24 15:41:321,125.002612,936.25O
2021-06-24 15:38:061,125.006006,750.00O
2021-06-24 15:38:021,125.006006,750.00O
View all Renalytix Ai trades in real-time

Renalytix Ai (RENX) Top Chat Posts

Renalytix Ai Daily Update: Renalytix Ai Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix Ai was 1,105p.
Renalytix Ai Plc has a 4 week average price of 1,050p and a 12 week average price of 924p.
The 1 year high share price is 1,220p while the 1 year low share price is currently 415p.
There are currently 72,047,286 shares in issue and the average daily traded volume is 72,219 shares. The market capitalisation of Renalytix Ai Plc is £810,531,967.50.
wan: Just listened to the excellent and very informative conference call. My impression is that managements confidence is very high indeed, but a good slug of restraint is also being deployed. During the call James McCullough discussed that previously he would not allow fixed overheads to build e.g. key hires to drive its commercialization strategy in the United States......until payment was secured or there was a clear line-of-sight on revenues. Recent news says quite a lot then in this regard - Renalytix AI PLC Key new hires to drive commercialization strategy 07/06/2021 NEW YORK and SALT LAKE CITY, June 7, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces a series of key hires to drive its commercialization strategy in the United States market in light of the recently announced Federal Government General Service Administration payment contract and additional large healthcare system partnerships. The combined background and experience of the new leadership team is expected to drive adoption of the KidneyIntelX testing and care model implementation in early-stage diabetic kidney disease populations. Renalytix expects to continue expanding its sales, marketing, and implementation teams with expected KidneyIntelX roll-out beginning in the VA Medical Health System in the 2(nd) half of 2021, and as the Company positions for a broader national expansion beginning in fiscal 2022 in line with expectations for a national Medicare insurance coverage determination later this year. Full release - hTTps:// From what I can gather, expansion of the team continues! I am also very optimistic regarding pharma partnerships given the increasing in-bound enquiries being received by Renalytix, and thus the expectation of a growing pharma services revenue line going forwards. There will be further news updates as we go through the remainder of 2021 e.g. Davita etc.
pugugly: Still burning cash but lots of dry powder - Some very impressive contracts signed at apparently good margins - No indication that I can see at a quick gkance when they might become cash flow positive or wheter the growing revenue momentum will enable them to raise further funds - if needed - at a premium to current share price.
mr roper: Agree with that, wan. My view is that the management have executed the plan superbly to date. The latest two partnerships seem only just be sinking in Stateside and more and more investors are becoming aware of Renx. Results should be due in the next 10 days. Hopefully we’ll get the first sign of small revenue coming through and it’ll peak the interest of a few more potential investors. If the management execute to plan my expectation is a $10bn mkt cap in 24 mths, as a result I still think Renx is better value now than at 250p. NB I looked at exact sciences earlier...$19bn mkt cap..revenue of $1.4bn last year and loss making.... Imagine a scenario of Renx having revenue of $300-500m but the majority dropping to the bottom line in profit...mkt cap...?
wan: I note the CEO sold a small percentage of his holding, which was into strength and a rising share price across two days, when clearly there was notable demand for stock (in the US where the shares were sold the shares finished up at $32.57 equivalent to £11.48 per share). I further note that such selling is strictly limited to specific times much like UK rules - Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, or inside information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future. I am not phased by the sale, nor the alignment with the rule above in terms of not being in possession of non-public information etc, as Renalytix has guided the market to expect further partnerships. From the Half-Year Report - We expect to announce additional partnerships during the current fiscal year ending June 30, 2021. We expect to announce five to seven partnerships before the end of calendar 2021. We believe these additional partnerships could materially increase patient and physician access to KidneyIntelX throughout the course of calendar 2021 in advance of broader insurance coverage. hTTps://
wan: More excellent news announced and today - NEW YORK, CHARLOTTE AND WINSTON-SALEM, N.C., May, 19 2021 -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), Atrium Health , Wake Forest Baptist Health and Wake Forest School of Medicine announced a partnership to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The KidneyIntelX bioprognostic platform for early-stage diabetic kidney disease risk assessment will be available through Atrium Health's electronic health record (EHR) system, providing access to primary care physicians, endocrinologists, nephrologists and care teams throughout 37 hospitals and more than 1,350 care locations across the Carolinas and Georgia. Charlotte, North Carolina-based Atrium Health serves more than 7 million people in the region, providing care under the Wake Forest Baptist Health name in the Winston-Salem, N.C. region and Atrium Health Navicent in Georgia. The partnership with Renalytix enables focused population health initiatives in kidney disease and will provide real-world evidence of optimized delivery of care, improved quality of life, and reduced healthcare costs. hTTp://
ramridge: If you overlay the share price chart of RENX (UK) to RNLX (US) over say the last 12 months, you will see a near identical match. What does it mean? Well there is no point in looking at the US for any lead or pointers. They are in sync and that's it.
red171: Anyone interested in a tax question in connection with the distribution as a dividend in specie of VRCI shares to us RENX SHs? It seems like a RENX question about distribution rather than a VRCI question. Am I right in thinking that the distribution by RENX of VRCI shares as a dividend in specie is taxable as income, like other dividends, at the amount RENX attributes to VRCI value/number of shares in issue at record date 10 July 59,614,134? Usually a company would issue a dividend voucher to confirm details - where can those details be found? Do we have to wait for YE accounts to see the distribution information after the capital reduction entries that made it possible. If right, the VRCI shares we received without paying would then have a notional capital cost of the dividend value assessed under income tax. & any others received in placing have a CGT cost at what we actually paid out in the placing (20p?) Many thanks in advance
donald pond: I just can't make sense of those margins. I had in mind the basic cost was $925 a test, and while we may share a big chunk of that with third parties, surely the margin is still going to be very high?There's a chap on twitter, Dirk Gently, who was also explaining VRCI to me, he knows his stuff and that looks great.I do love the free spin off shares these companies generate. We got one VRCI share we got for each RENX one, so for anyone holding from that time you can add another 70p to the RENX share price to work out where you are.
wan: There are many reasons for Renalytix Valuation, such as the track record, experience, and connections of the management team, which includes a deep relationship with Mount Sinai (a significant shareholder and launch partner) which encompasses the Icahn School of Medicine at Mount Sinai and eight hospital campuses in the New York metropolitan area. Importantly, each year kidney disease kills more people than breast and prostate cancer. Not to mention that the FDA has granted Breakthrough Device designation to KidneyIntelX™ 'effectively' demonstrating that both of the following criteria are met: 1. The device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions 2, The device also meets at least one of the following: 1. Represents Breakthrough Technology 2. No Approved or Cleared Alternatives Exist 3. Offers Significant Advantages over Existing Approved or Cleared Alternative 4. Device Availability is in the Best Interest of Patients FDA grants Breakthrough Device designation to KidneyIntelX™ MAY 2, 2019 Provides priority regulatory review of AI-enabled diagnostic for fast-progressing kidney disease Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA), for its lead diagnostic, KidneyIntelX™. This is the first such designation for an AI-enabled diagnostic for kidney disease publicly announced by any company. KidneyIntelXTM is designed to diagnose and improve clinical management of patients with Type II diabetes with fast-progressing kidney disease, in an effort to curtail the estimated $114 billion annual cost1 of chronic and end-stage kidney disease to the United States healthcare system. The diagnostic will use machine learning algorithms to assess the combination of predictive blood-based biomarkers, including sTNFR1, sTNFR2 and KIM1, in combination with electronic health record information, to identify progressive kidney disease. KidneyIntelXTM is being developed in close collaboration with the Mount Sinai Health System. The FDA’s Breakthrough Devices Program is a voluntary programme for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the programme is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment and review, while preserving the statutory standards for premarket approval, 510(k) clearance and De Novo marketing authorisation, consistent with the Agency’s mission to protect and promote public health. Sally Bowden, Chief Operating Officer of RenalytixAI, said: “This designation is a significant advancement towards our goal of bringing to market a solution that can greatly improve the identification and treatment of patients with chronic kidney disease. We look forward to continuing to work closely with the FDA through this process, including on our data development plan, our clinical validation and our subsequent submission for regulatory clearance.” Erik Lium, PhD, Executive Vice President of Mount Sinai Innovation Partners, said: “We’re pleased RenalytixAI has received Breakthrough Designation for KidneyIntelX, providing the opportunity to work hand-in-hand with the FDA towards the goal of FDA submission. Renal disease represents an increasing healthcare crisis globally, and early detection and intervention is essential in changing the course of this disease.” A copy of the FDA’s guidelines on the Breakthrough Devices Program can be found at GuidanceDocuments. Notes: [1] United States Renal Data System – hxxps:// The person responsible for arranging the release of this announcement on behalf of the Company is James McCullough, CEO. hTTps:// The collaboration with a pharmaceutical and biopharmaceutical giant, AstraZeneca, to improve outcomes for patients with chronic disease (not just CKD) is another example, with the results from the program anticipated in early 2021 - NEW YORK, August 21, 2020 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the collaboration will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to examine further improving outcomes for patients with chronic kidney disease (CKD) and its complications, in coordination with the Mount Sinai Health System. The goal of the first stage is to help improve guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software. hTTps:// Both of the above are just two aspects amongst many that are advanced, including a successful spinout of Verici with a retained shareholding, formation of Kantaro and many other advanced developments and partnerships, with Renalytix engaging with multiple healthcare institutions and national payors regarding additional partnership opportunities. Amongst the many developments, either of the above FDA approval or AstraZeneca collaboration could have a material and positive effect on the share price. With the AstraZeneca collaboration further demonstrating that Renalytix technology offering is an artificial intelligence-enabled in vitro diagnostic 'platform' capable of addressing other diseases, it will be interesting to see where else this powerful platform might be deployed. Renalytix Chief Executive Officer Mr. James McCullough, was previously CEO at Exosome Diagnostics, a cancer diagnostics firm that was acquired by Bio-Techne Corporation in 2018.
74tom: The nice thing here is that a higher RENX share price is beneficial to Mount Sinai as it increases the value of their 15% stake. A larger portion of Kantaro may also reduce RENX's need for future equity funding, so there are a few reasons why this might happen. It's a fascinating & pretty unique situation that is unfolding.
Renalytix Ai share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 02:59:13